ABBVIE

ABBVIE

Displaying 10 out of 11 results

  1. FILE PHOTO: A screen displays the share price for drugmaker AbbVie on the floor of the New York Sto

    AbbVie leans on new treatments to forecast upbeat 2020 profit

    AbbVie Inc on Friday forecast 2020 earnings above Wall Street estimates as the drugmaker expects growth to be powered by its new treatments for ...
  2. The Allergan logo is seen in this photo illustration

    AbbVie-Allergan US$63 billion deal aided by Nestle, AstraZeneca buys

    U.S. drugmaker AbbVie's US$63 billion tie-up with Allergan is getting help from Nestle and AstraZeneca buying up products the Irish-domiciled ...
  3. FILE PHOTO: A screen displays the share price for pharmaceutical maker AbbVie on the floor of the N

    AbbVie boosts 2019 profit outlook as Humira helps beat revenue estimates

    AbbVie Inc posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, helped by strong demand for ...
  4. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stoc

    AbbVie terminates late-stage lung cancer trial

    AbbVie Inc on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed ...
  5. The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey

    Merck's biosimilar to AbbVie's Humira wins FDA approval

    The U.S. Food and Drug Administration approved Merck & Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the ...
  6. FILE PHOTO: The Allergan logo is seen in this photo illustration in Singapore

    AbbVie looks beyond Humira with US$63 billion deal for Botox-maker Allergan

    AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than US$60 billion, the Wall Street Journal reported on Tuesday, citing ...
  7. A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stoc

    AbbVie halts enrollment after brain cancer trial misses goal, shares fall

    AbbVie Inc said on Friday it has halted enrollment of patients in all ongoing studies testing its brain cancer treatment after the drug failed to ...
  8. FILE PHOTO:  A trader works by the post that trades AbbVie on the floor of the New York Stock Excha

    AbbVie's Skyrizi drug to treat psoriasis wins US approval

    AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when ...